Authors
Latest:
CAR-T Cells: The Next Era in Immuno-OncologyAn update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.
Latest:
The Potential Impact of CAR T-Cell Treatment Delays on SocietyTreatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Latest:
The Potential Impact of CAR T-Cell Treatment Delays on SocietyTreatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Latest:
Reimbursement and Managed Care News for January 2008Topics covered in this issue include:1) Dosing Patterns and Costs of Erythropoesis-Stimulating Agents in Patients With Cancer2) New Practice Guideline Updates Treatment of Nonâ%uFFFD%uFFFDSmall Cell Lung Cancer3) Large Health Insurer Begins Genetic Risk Counseling for Cancer4) Multiple Myeloma Guidelines Now Include Combination Therapy With Bortezomib5) Survey Finds That Managed Car Executives Are Misinformed About the Value and Cost of Cancer Biologics
Latest:
Nirav Shah, MD, on the Potential of Dual-Targeted CAR-T in Chronic Lymphocytic LeukemiaThe associate professor of medicine at Medical College of Wisconsin discussed clinical results from patients with CLL and Richter’s transformation treated with CD19/CD20-targeted CAR-T LV20.19.
Latest:
Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in LymphomaIra Braunschweig, MD, discusses mitigating the toxicities that are associated with CAR T-cell therapy in lymphoma.
Latest:
Dr. Neelapu on Managing Toxicities Associated with CAR T-Cell Products in LymphomaSattva Neelapu, MD, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.
Latest:
Dr. Leslie on the Development of CAR T-Cell Therapy in DLBCL and MCLLori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.
Latest:
CAR T-Cell Therapy Enters a New Era in Lymphomas, But More Lessons to LearnBrian T. Hill, MD, PhD, discusses the advent of CAR T-cell therapies, such as axicabtagene ciloleucel, tisagenlecleucel, and brexucabtagene autoleucel, and how they have shifted lymphoma treatment into a new era.
Latest:
Axi-cel Approved by European Commission for Second-Line Treatment of Adults With DLBCL/HGBLThe approval was based on data from ZUMA-7, a phase 3 clinical trial.
Latest:
Dr. Kahl on the Utility of Tafasitamab/Lenalidomide in DLBCLBrad S. Kahl, MD, discusses the utility of tafasitamab combined with lenalidomide in patients with diffuse large B-cell lymphoma who are ineligible for CAR T-cell therapy.
Latest:
CAR T Pioneers Describe Challenges Faced in CancerAdvances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.
Latest:
Liso-Cel Approved for R/R B-Cell Lymphoma by European CommissionThe decision was based on findings from the phase 1 TRANSCEND NHL 001 clinical trial.
Latest:
Nikhil Munshi, MD, on Final Data on Cilta-Cel in Multiple Myeloma From CARTITUDE-1The associate professor from Dana Farber Cancer Center and Harvard Medical School discussed continued efficacy and safety data presented at the 2023 EHA Meeting.
Latest:
Adriana Rossi, MD and Luciano J. Costa, MD, PhD on Earlier CAR T in Multiple MyelomaOncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.
Latest:
CAR T-Cell Therapy for Multiple Myeloma: What Community Oncologists Need to KnowThe emergence of cellular-based therapies represents a major opportunity to improve outcomes in the heavily pretreated and refractory myeloma population.
Latest:
Dr. Deol on the Curative Potential of CAR T-Cell Therapy in ALLAbhinav Deol, MD, discusses the role of CAR T-cell therapy in pediatric patients with acute lymphoblastic leukemia.
Latest:
Dr. Bachier on the Potential Benefits of Liso-Cel in DLBCLCarlos R. Bachier, MD, discusses the investigational CAR T-cell therapy lisocabtagene maraleucel in diffuse large B-cell lymphoma.
Latest:
Dr. Gajra on Adverse Effects Associated With CAR T-Cell Therapy in Hematologic MalignanciesAjeet Gajra, MD, FACP, discusses adverse effects associated with CAR T-cell therapy in hematologic malignancies.
Latest:
Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple MyelomaJesus G. Berdeja, MD, discusses the dosing of the investigational CAR T-cell product JNJ-4528 in patients with relapsed/refractory multiple myeloma.
Latest:
Real-World Axi-Cel Data Show QOL Improvements in LBCLThe first year after treatment yielded statistically significant improvements in overall QOL and symptoms within the first year of treatment for relapsed/refractory large B-cell lymphoma
Latest:
New Project Aims to Increase CAR T Safety, AvailabilityA new project is manufacturing a “purified” version of CAR-T-cells currently used to treat types of lymphoma and leukemia.
Latest:
Dr. Brody on Managing CAR T-Cell Therapy Toxicities in MCLJoshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.
Latest:
Dr. Davids on the Future of CAR T-Cell Therapy in CLLMatthew S. Davids, MD, MMSc, discusses the future of CAR T-cell therapy in chronic lymphocytic leukemia.
Latest:
Dr. Mesa on the Potential Utility of CAR T-Cell Therapy in MPNsRuben A. Mesa, MD, discusses the potential utility of CAR T-cell therapy in myeloproliferative neoplasms.
Latest:
Dr. Abid on Challenges With CAR T-Cell Therapy During the COVID-19 PandemicMuhammad Bilal Abid, MD, MRCP, discusses challenges with CAR-T cell therapy during the coronavirus disease 2019 pandemic.
Latest:
Dr. Kansagra on Updates With CAR T-Cell Therapy in Hematologic CancersAnkit Kansagra, MD, discusses key updates with CAR T-cell therapy in hematologic cancers.
Latest:
CAR T-Cell Research SurgesHundreds of trials are under way, 3 CAR T-cell therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma.
